{"url_path":"/sec/xbio/8-k/2026-05-13/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1534525/0001683168-26-003766-index.html","accession_number":"0001683168-26-003766","cik":"0001534525","ticker":"XBIO","issuer_name":"Xenetic Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1534525/0001683168-26-003766-index.html","primary_entity_key":"0001534525","primary_entity_name":"Xenetic Biosciences, Inc."},"word_count":317,"has_tables":true,"body_markdown":"Xenetic Biosciences, Inc. 8-K\n\nfalse\n0001534525\n\n0001534525\n\n2026-05-13\n2026-05-13\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n**________________________**\n\n \n\n**FORM 8-K**\n\n________________________\n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d) of The\nSecurities Exchange Act of 1934**\n\n \n\nDate of Report (Date of earliest event\nreported): **May 13,\n2026**\n\n________________________\n\n \n\n**Xenetic Biosciences,\nInc.**\n\n(Exact name of registrant as specified in charter)\n\n \n\n**Nevada**\n \n**001-37937**\n \n**45-2952962**\n\n(State or other jurisdiction\n\nof incorporation)\n \n(Commission\n\nFile Number)\n \n(IRS Employer\n\nIdentification No.)\n\n \n\n**945\nConcord Street******\n \n\n**Framingham, Massachusetts**\n**01701**\n\n(Address of principal executive offices)\n(Zip Code)\n\n \n\n**(781)****778-7720**\n\n(Registrant’s telephone number, including\narea code)\n\n** **\n\n**Not Applicable**\n\n(Former name or former address, if changed since\nlast report)\n\n \n\nCheck the appropriate box below if the\nForm 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see\nGeneral Instruction A.2. below):\n\n \n\n☐    Written communications\npursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n☐    Soliciting material\npursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n☐    Pre-commencement\ncommunications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n☐    Pre-commencement\ncommunications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b)\nof the Act:\n\n \n\n**Title of each class**\n \n**Trading Symbol(s)**\n \n**Name of each exchange on which registered**\n\nCommon Stock, $0.001 par value per share\n \nXBIO\n \nThe\nNasdaq Stock Market\n\n \n\nIndicate by check mark whether the registrant\nis an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities\nExchange Act of 1934 (17 CFR §240.12b-2).\n\nEmerging growth company ☐\n\n \n\nIf an emerging growth company, indicate by check\nmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting\nstandards provided pursuant to Section 13(a) of the Exchange Act. ☐"}